Gold nanoparticle aggregates (red) are observed inside triple negative breast cancer cells after an enzyme-activated assembly and internalization process.
(photo credit: Richard Huang and Ye He)
The breakthrough advance could lead to a novel, drug-free therapeutic that can slow, possibly stop, the growth of cancer cells
A multi-institutional research team has designed nanoparticles that can communicate with and slow the development of cancer cells. The work — detailed in a newly published paper in Advanced Materials — has uncovered a novel framework for the potential development of drug-free cancer therapies.
Led by scientists at the Advanced Science Research Center at the Graduate Center, CUNY (CUNY ASRC), the research team was able to design nanoparticles that are activated to self-assemble when they encounter cancer cells and send messages to instruct the cells to slow their growth. Because the nanoparticles communicate only with the cancer cells, the surrounding healthy cells aren’t impacted.
“Cancer cells take up materials from their environment, and they also secrete factors that help them degrade surrounding tissue in order to spread and metastasize,” said Richard Huang, lead author of the paper, a Ph.D. student at the Graduate Center, CUNY (GC CUNY), and a researcher with the CUNY ASRC Nanoscience Initiative and the Center for Discovery and Innovation at CUNY’s City College of New York (CCNY). “We made particles that respond to both of these characteristics by aggregating into clusters that are actively taken up by cancer cells. Once inside, they appear to be able to reduce the cancer cells’ metabolic activity and consequently reduce their growth.
One reason the progression of cancer is difficult to control is that the cells secrete an abnormally large amount of the matrix metalloproteinase-9 (MMP-9) enzyme, which breaks down the collagen that holds together healthy tissue. The research team was able to use this feature against the cancer cells. This is achieved by designing nanoparticles that when triggered by MMP-9, begin assembling to large aggregates in the cells’ vicinity. The cells engulf these aggregates, and their size causes physical distress to the cancer cells and reduces their ability to proliferate and survive.
One highlight of the study is that the researchers were able to use confocal reflection microscopy to visualize the nanoparticle aggregates inside the cancer cells in real-time. “This label-free, live imaging technique allowed us to have a closer look at when and where the aggregates were formed, and how the cancer cells respond to the particles at the sub-cellular level,” said Ye He, director of the Live Imaging and Bioenergetics Facility in the CUNY ASRC Neuroscience Initiative.
“Through this research, we wanted to determine whether it’s possible to make use of relatively simple peptide design to create nanoparticles that could produce robust self-assembly in biological media and have an impact on cancer cells,” said Rein Ulijn, director of the CUNY ASRC Nanoscience Initiative and the study’s principal investigator. “While this is early-stage research, the findings provide exciting possibilities for a drug-free therapeutic treatment that could be extremely useful for cancer patients who have developed drug resistance and for extending the lives of people with metastatic cancer.”
Further studies are needed to fully access the therapeutic potential of the team’s discovery.
Original Article: Scientists Design Nanoparticles That Communicate With Cancer Cells
More from: City University of New York | University of Strathclyde | Weizmann Institute of Science
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Self-assembling nanoparticles
- A magnetic liquid makes for an injectable sensor in living tissue
The researchers used their substance to make liquid bioelectronics that can be injected into the body and later retrieved. These devices seamlessly attach to biological tissue and convert ...
- Taking the bite out of snake venom
More effective treatments for snakebites that afflict millions of people worldwide every year are emerging from EU research.
- Scientists learn from caterpillars how to create self-assembling capsules for drug delivery
Self-assembling molecules that spontaneously organize themselves to form complex structures are common in nature. For example, the tough outer layer of insects, called the cuticle, is rich in proteins ...
- Self-assembling synthetic cells act like living cells with extra abilities
For the new study, scientists from the University of North Carolina at Chapel Hill developed synthetic, self-assembling cytoskeletons, built out of DNA, peptides and other genetic material. “DNA does ...
- Smart nanoprobe illuminates prostate cancer cells, reveals research
Biomedical imaging modalities such as magnetic resonance imaging (MRI) have revolutionized the ability to detect and track the progress of many cancer types. However, the difficulty of ...
Go deeper with Google Headlines on:
Self-assembling nanoparticles
[google_news title=”” keyword=”self-assembling nanoparticles” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Drug-free cancer treatment
- Pfizer, Genmab’s ADC Tivdak Scores Full FDA Approval in Recurrent or Metastatic Cervical Cancer
Based on strong overall and progression-free survival data in its Phase III confirmatory study, Pfizer and Genmab’s antibody-drug conjugate Tivdak on Monday secured the FDA’s full approval for ...
- Is Ozempic the New Anti-Inflammatory Wonder Drug?
Some GLP-1s are now FDA approved for chronic weight management, including Wegovy (semaglutide) and Saxenda (liraglutide), while others like Ozempic (semaglutide) are approved for type 2 diabetes but ...
- Tivdak Gets Traditional Approval for Recurrent or Metastatic Cervical Cancer
The Food and Drug Administration (FDA) has granted full approval to Tivdak ® (tisotumab vedotin-tftv) for the treatment of patients with recurrent or metastatic cervical cancer with disease ...
- MorphoSys Says Novartis Deal Progressing Steadily Despite Safety Concerns Over Bone Marrow Cancer Drug, Pelabresib
MorphoSys faces safety concerns over pelabresib, a myelofibrosis treatment. Physicians report patients transitioning rapidly to acute myeloid leukemia. FDA alerted. Novartis acquisition proceeds ...
- AstraZeneca, Daiichi tout Enhertu trial win in earlier, broader HER2-low breast cancer
AstraZeneca and Daiichi Sankyo’s trailblazing Enhertu appears to have outdone itself. | AstraZeneca and Daiichi Sankyo’s trailblazing Enhertu appears to have outdone itself. After spearheading the new ...
Go deeper with Google Headlines on:
Drug-free cancer treatment
[google_news title=”” keyword=”drug-free cancer treatment” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]